Summary by Moomoo AI
On March 4, 2024, BioVie Inc., a Nevada-based biopharmaceutical company, filed an amended Current Report on Form 8-K/A with the Securities and Exchange Commission. The amendment was made to include additional exhibits related to a previously reported event where BioVie entered into a placement agent agreement with ThinkEquity LLC. This agreement pertains to the issuance and sale of up to 21 million shares of BioVie's Class A common stock and/or pre-funded warrants, along with purchase warrants for up to 10.5 million shares. The shares and pre-funded warrants are offered to investors at $1.00 per share and $0.9999 per pre-funded warrant, respectively. The amendment adds Exhibits 5.1, 5.2, 23.1, and 23.2 to the original filing, which include legal opinions and consents from Sherman & Howard L.L.C. and Reed Smith LLP. No other information in the original Form 8-K has been amended.